News | August 02, 2021
Ajanta Pharma aims to file 10-12 ANDAs per annum
India business is growing as per projections; whereas US business will bounce back soon.
India business is growing as per projections; whereas US business will bounce back soon.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
Price band in the range of Rs 933 to Rs 954
It posted net profit of Rs.147.76 crores for the period ended June 30, 2020.
The company posted net profit of Rs.2.43 crores for the period ended June 30, 2020.
The group now has 320 approvals and has so far filed over 400 ANDAs
It posted net loss of Rs.(2429.81) crores for the period ended June 30, 2020.
Subscribe To Our Newsletter & Stay Updated
